跳至主要内容
临床试验/NCT07690111
NCT07690111招募中不适用

International Registry for TRPM3-associated Disorders

Charite University, Berlin, Germany1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
100
试验地点
1
主要终点
Developmental Delay

研究概览

简要总结

The goal of the TRPM3Care-registry is to record the disease progression of patients with TRPM3-associated disorders. This allows us to compare the disease progression and the success of different therapies, as well as to examine their impact on quality of life.

详细描述

Transient Receptor Potential Melastatin 3 (TRPM3) is a calcium-permeable, non-selective cation channel that is widely expressed in the central and peripheral nervous system, sensory neurons, pancreatic β-cells, vascular smooth muscle, and several other tissues. TRPM3 plays an essential role in intracellular calcium signaling and contributes to neuronal excitability, thermosensation, nociception, insulin secretion, and cellular homeostasis.

Over the past decade, pathogenic germline variants in TRPM3 have been identified as the cause of a rare neurodevelopmental disorder characterized by developmental delay, intellectual disability, epilepsy, hypotonia, movement disorders, and variable neurobehavioral manifestations. The clinical spectrum is expanding as additional patients are identified through next-generation sequencing, revealing considerable phenotypic variability and an incomplete understanding of genotype-phenotype relationships.

Due to the rarity of TRPM3-associated disorders, clinical knowledge is currently limited to relatively small case series and individual case reports. Consequently, there is an urgent need for systematic collection of standardized clinical, genetic, imaging, electrophysiological, and longitudinal outcome data to better characterize the natural history of these disorders and to facilitate future therapeutic research.

Purpose of the Registry

The TRPM3Care Registry is an international, multicenter observational registry established to collect comprehensive clinical and molecular data from individuals carrying pathogenic or likely pathogenic variants in the TRPM3 gene, as well as individuals with variants of uncertain significance when supported by compatible clinical findings.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Variant in the TRPM3 gene

排除标准

  • no consent from patient/familiy

结局指标

主要结局

Developmental Delay

时间窗: 10 years

Development in patients

次要结局

  • Epilepsy(10 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Lena-Luise Becker

Principal Investigator

Charite University, Berlin, Germany

研究点 (1)

Loading locations...

相似试验